Sugi Predict

Sugi Predict / Compounds / SCHEMBL2582436

SCHEMBL2582436

SCHEMBL2582436

COC(=O)c1cc(F)cnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ OPRK1 P41145 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.42
▸ ABL1 P00519 1/20 0.40
▸ MAPT P10636 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ GAA P10253 2/20 0.38
▸ SLC6A4 P31645 1/20 0.38
▸ SLC6A3 Q01959 1/20 0.38
▸ ALDH1A1 P00352 3/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.38
▸ HPGD P15428 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ CASP3 P42574 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ SENP8 Q96LD8 1/20 0.38
▸ SENP7 Q9BQF6 1/20 0.38
▸ SENP6 Q9GZR1 1/20 0.38
▸ ATR Q13535 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ SERPINH1 P50454 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1325330 0.98 OPRK1 (0.45) OPRK1KDM4EABL1MAPTL3MBTL1
SCHEMBL20010499 0.83 OPRK1 (0.35) OPRK1ABL1SCN5ASCN9A
SCHEMBL473981 0.82 OPRK1 (0.48) OPRK1KDM4EABL1MAPTL3MBTL1
SCHEMBL15636128 0.82 OPRK1 (0.48) OPRK1KDM4EMAPTL3MBTL1GAA
SCHEMBL30816026 0.82 OPRK1 (0.48) OPRK1KDM4EABL1MAPTL3MBTL1
SCHEMBL2086658 0.82 CASP1 (0.47) KDM4EMAPTL3MBTL1GAAALDH1A1
SCHEMBL30849485 0.82 CA12 (0.41) KDM4EMAPTL3MBTL1ALDH1A1HPGD
SCHEMBL29149064 0.82 CA12 (0.41) KDM4EMAPTL3MBTL1ALDH1A1HPGD
SCHEMBL29172982 0.82 CYP1A2 (0.38) OPRK1ABL1SCN5ASCN9A
SCHEMBL3520084 0.81 MAPK1 (0.47) KDM4EABL1MAPTL3MBTL1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS NFLECTION THERAPEUTICS INC (US) 2025-12-25 — — US disclosed
EP-4649077-A1 SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF Cerevel Therapeutics, LLC (US) 2025-11-19 — — EP disclosed
CN-115515685-B EIF4E inhibitors and uses thereof 皮克医疗公司 2025-04-08 — — CN disclosed
CN-119215031-A Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer 恩福莱克逊治疗有限公司 2024-12-31 — — CN disclosed
US-12157731-B2 EIF4E inhibitors and uses thereof PIC Therapeutics, Inc. (US) 2024-12-03 — — US disclosed
CN-113660931-B Arylaniline and heteroaryl aniline compounds for the treatment of skin cancer 恩福莱克逊治疗有限公司 2024-10-11 — — CN disclosed
CN-113645964-B Arylaniline and heteroaryl aniline compounds for fetal treatment 恩福莱克逊治疗有限公司 2024-10-11 — — CN disclosed
WO-2024151833-A1 SPIRO DERIVATIVES AS M4 ACTIVATORS/MODULATORS AND USES THEREOF CEREVEL THERAPEUTICS, LLC (US) 2024-07-18 — — WO disclosed
EP-3972965-B1 PYRIDINONE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS AGAINST HIV INFECTED CELLS MERCK SHARP & DOHME LLC (US) 2024-07-03 — — EP disclosed
CN-117946097-A Vitamin Li Xigu, intermediate thereof and preparation method 上海医药工业研究院有限公司 2024-04-30 — — CN disclosed
EP-1756042-A1 SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS Pfizer, Inc. (US) 2007-02-28 — — EP disclosed
EP-1740211-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS Pfizer Products Incorporated (US) 2007-01-10 — — EP disclosed
EP-1663979-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2006-06-07 — — EP disclosed
US-20050267170-A1 Substituted methyl aryl or heteroaryl amide compounds PFIZER INC 2005-12-01 — — US disclosed
WO-2005105732-A1 SUBSTITUTED METHYL ARYL OR HETEROARYL AMIDE COMPOUNDS PFIZER JAPAN INC. (JP) 2005-11-10 — — WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
WO-2005102389-A2 COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS PFIZER PRODUCTS INC. (US) 2005-11-03 — — WO disclosed
CN-1613849-A Preparation of 2-Cl-5-F-nicotinate and nicotonic acid YAOMING KANGDE MEDICINE DEVELO (CN) 2005-05-11 — — CN disclosed
US-20050065188-A1 Aryl or heteroaryl amide compounds ASKAT INC. (JP) 2005-03-24 — — US disclosed
WO-2005021508-A1 PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS PFIZER INC. (US) 2005-03-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12157731-B2 EIF4E inhibitors and uses thereof EIF4E, EIF4EBP1, EIF4A1 OPRK1 3949/4885KDM4E 710/4885ABL1 888/4885
US-20050065188-A1 Aryl or heteroaryl amide compounds HRH2, PTGER1, LTB4R2 OPRK1 23/4885KDM4E 875/4885ABL1 1117/4885
US-20050267170-A1 Substituted methyl aryl or heteroaryl amide compounds PTGER1, PTGER2, PTGER3 OPRK1 18/4885KDM4E 963/4885ABL1 287/4885
US-20250387379-A1 ARYL-ANILINE AND HETEROARYL-ANILINE COMPOUNDS FOR TREATMENT OF SKIN CANCERS SUB1, AHR, NCOA3 OPRK1 1242/4885KDM4E 2358/4885ABL1 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.